Core Insights - The research conducted by Baiyunshan Zhongyi Pharmaceutical has achieved a significant breakthrough in traditional Chinese medicine (TCM) applied to reproductive medicine, with results published in the prestigious journal Nature Communications [1][2] - This study marks the first clinical research results on TCM in reproductive medicine to be featured in Nature Communications, providing a new case for evidence-based research in this field [1] Group 1: Research Details - The clinical trial was a multi-center, prospective, double-blind, placebo-controlled randomized study involving 1,467 women aged 35-42 undergoing fresh embryo transfer via IVF/ICSI [1] - The study found that the Zishen Yutai Pill significantly increased the live birth rate in older women (≥35 years) during fresh embryo transfer cycles, with a relative increase of approximately 23% (RR≈1.23) [2] Group 2: Publication and Impact - The research paper titled "Zishen Yutai Pill increased live births in advanced maternal age women: A randomized clinical trial" has been published online in Nature Communications, which has a high impact factor of 15.7, known for its rigorous academic review [2] - Following the publication of these high-level research results, there have been requests from research and medical institutions in Europe and the United States to conduct joint trials or register the product for sale [2]

Group 1 - The core message of the article highlights that Baiyunshan's proprietary traditional Chinese medicine, Zishen Yutai Wan, has achieved a significant breakthrough in clinical research, published in the prestigious journal Nature Communications, marking a first for TCM in reproductive medicine [1] - The study, led by professors from Sun Yat-sen University and Yale University, involved a multi-center, prospective, double-blind, placebo-controlled trial with 1,467 women aged 35-42 undergoing IVF/ICSI fresh transfers [1] - Baiyunshan Zhongyi Pharmaceutical is now one of the few TCM companies in China to publish clinical research in the Nature series of journals, setting a new high for SCI impact factors in gynecological TCM clinical research [1] Group 2 - The research focuses on the efficacy of Zishen Yutai Wan in improving live birth rates among older women undergoing assisted reproductive technology [1] - Baiyunshan Zhongyi Pharmaceutical is advancing its production capabilities by adopting "Traditional Chinese Medicine Industry 4.0," integrating big data, industrial internet, and AI technologies to ensure product quality [1] - The company aims to promote traditional Chinese medicine on a global scale through its innovative and intelligent production lines [1]

临床研究结果表明，滋肾育胎丸能够显著提高高龄（≥35岁）妇女的新鲜胚胎移植周期活产率，活产率 相对提升约23%。此次临床研究基于规范的临床研究设计，提供了较为可靠的循证医学证据，进一步支 持滋肾育胎丸在辅助生殖中的应用价值，为高龄女性实现生育目标提供了具有现实意义的临床选择。 据介绍，此次滋肾育胎丸的临床研究采用多中心、前瞻性、双盲、安慰剂对照的随机临床试验设计，在 12家三级甲等医院生殖中心开展，共纳入1467名35—42岁接受IVF/ICSI新鲜胚胎移植的妇女。研究结果 显示，滋肾育胎丸组活产率达23.3%，显著高于安慰剂组的19.0%，相对增幅约23%，同时妊娠试验阳性 率、胚胎种植率及临床妊娠率均得到明显改善。该药物在提升疗效的同时，未增加母婴不良事件风险。 记者从白云山（600332）获悉，该公司旗下白云山中一药业滋肾育胎丸循证医学临床研究获得重大突 破，相关研究成果在国际顶级学术期刊《自然》的子刊《自然-通讯》在线发表，这也是《自然-通讯》 首次发表关于中医药在生殖医学应用的临床研究成果。 目前，白云山中一药业围绕滋肾育胎丸开展了包括药理、毒理、多中心循证研究项目，产品及治疗方案 被写入《中医妇科 ...

Group 1 - Guangzhou Pharmaceutical Group Co., Ltd. (referred to as "Guangyao Group") has achieved a significant breakthrough with its product Zishen Yutai Pill, which has shown to significantly increase live birth rates in women of advanced maternal age (≥35 years) during fresh embryo transfer cycles by approximately 23% (RR≈1.23) [1][2] - The clinical research results of Zishen Yutai Pill were published in the prestigious journal Nature Communications, marking the first time that a clinical study on traditional Chinese medicine in reproductive medicine has been recognized by an international top academic journal [1][2] - Following the publication of the high-level research results, several research and medical institutions in Europe and the United States have expressed interest in conducting joint trials or seeking drug registration for Zishen Yutai Pill [2] Group 2 - The impact factor of Nature Communications is 15.7, highlighting the journal's status as a leading academic publication [2] - Guangyao Group's subsidiary, Baiyunshan Zhongyi Pharmaceutical Co., Ltd., has conducted breakthrough research on Zishen Yutai Pill, focusing on pharmacology, toxicology, and multi-center evidence-based research projects to address clinical needs and industry standards [2]

转自：新华网 2025广药集团科技创新大会于2025年12月27日在广州举行，世界500强企业广药集团宣布"十五五"时期预计投入研发费用100-150亿元，产业投资与并购费 用200-300亿元，通过建立健全科技创新的容错机制，优化重大项目决策机制，推进科技创新布局，打造科技创新型企业。 坚定不移抓住科技创新这个"牛鼻子" 从产业维度看，我国生物医药行业正从"规模积累"向"价值创造"深度转型，创新是破解发展瓶颈的核心动能。广药集团首次以"科技创新"为主题，举行生 物医药行业的深度研讨与交流，明确以创新驱动为核心，全面推动战略转型，体现了世界500强医药企业的产业使命感与发展担当。 "要敢于创新，也贵在坚持。"中国工程院院士钟南山指出，新药研究之路本就充满不确定性，多数探索可能面临挫折，少数成功的突破有望实现国内乃至 世界范围内的领先。只有构建让科研人员敢于瞄准难题潜心钻研、不惧失败的良好环境，才能为生物医药领域突破性成果的孕育提供土壤。 "'十五五'时期是广药集团实现跨越式发展的黄金窗口，我们将始终锚定现代化、数字化、科技化、国际化的'四化'方向，坚定不移抓住科技创新这个'牛 鼻子'，再造一个新广药"。在当天 ...

Group 1 - The core viewpoint of the news is that Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has experienced a decline in stock price and significant net outflow of funds, indicating potential market challenges [1] - Baiyunshan's stock price decreased by 3.15% year-to-date, with a drop of 2.84% over the last five trading days and 2.54% over the last 20 days [1] - The company reported a revenue of 61.606 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, up 4.78% year-on-year [2] Group 2 - Baiyunshan's main business segments include traditional Chinese medicine, chemical raw materials, and health products, with the largest revenue contribution from the commercial sector at 69.32% [2] - The company has distributed a total of 10.906 billion yuan in dividends since its A-share listing, with 4.359 billion yuan distributed in the last three years [3] - As of September 30, 2025, Baiyunshan had 101,700 shareholders, an increase of 18.85% from the previous period [2]

Core Viewpoint - Baiyunshan Pharmaceutical Group's stock experienced a decline of 2.00% on January 7, with a trading volume of 851 million yuan, indicating a significant market activity and investor interest in the company [1]. Financing Summary - On January 7, Baiyunshan had a financing buy-in amount of 155 million yuan, with a net financing buy of 102 million yuan after repayments of 52.73 million yuan [1]. - The total financing and securities balance for Baiyunshan reached 1.066 billion yuan, which is 2.97% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - Baiyunshan's securities lending on January 7 included a repayment of 18,800 shares and a sale of 1,200 shares, with a total selling amount of 30,500 yuan, reflecting a relatively high level of securities lending activity [1]. Company Overview - Baiyunshan Pharmaceutical Group, established on September 1, 1997, and listed on February 6, 2001, is based in Guangzhou, Guangdong Province, and engages in the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2]. - The company's revenue composition includes 69.32% from large commercial operations, 16.79% from health-related products, and 12.53% from traditional Chinese medicine and other segments [2]. - As of September 30, 2025, Baiyunshan reported a revenue of 61.606 billion yuan, a year-on-year increase of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, reflecting a growth of 4.78% [2]. Dividend Information - Since its A-share listing, Baiyunshan has distributed a total of 10.906 billion yuan in dividends, with 4.359 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Baiyunshan include China Securities Finance Corporation, holding 47.278 million shares, and Hong Kong Central Clearing Limited, holding 20.0109 million shares, which saw a decrease of 20.4372 million shares compared to the previous period [3]. - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which experienced reductions in their holdings [3].

责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，1月5日，LSV Asset Management增持白云山（00874）3万股，每股作价 18.112港元，总金额约为54.34万港元。增持后最新持股数目为1101.92万股，最新持股比例为5.01%。 责任编辑：卢昱君 香港联交所最新资料显示，1月5日，LSV Asset Management增持白云山（00874）3万股，每股作价 18.112港元，总金额约为54.34万港元。增持后最新持股数目为1101.92万股，最新持股比例为5.01%。 ...

香港联交所最新资料显示，1月5日，LSV Asset Management增持白云山（600332）(00874)3万股，每股 作价18.112港元，总金额约为54.34万港元。增持后最新持股数目为1101.92万股，最新持股比例为 5.01%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月5日，LSV Asset Management增持白云山(00874)3万 股，每股作价18.112港元，总金额约为54.34万港元。增持后最新持股数目为1101.92万股，最新持股比 例为5.01%。 ...